title: Vaccine development against Trypanosoma cruzi and Chagas disease.
abstract: The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.
authors.affiliation: Centro de Investigación y Estudios Avanzados en Salud Animal, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Estado de México, Toluca, Mexico.
authors.forename: Juan C
authors.initials: JC
authors.lastname: Vázquez-Chagoyán
authors.forename: Shivali
authors.initials: S
authors.lastname: Gupta
authors.forename: Nisha Jain
authors.initials: NJ
authors.lastname: Garg
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D016827:CD8 Antigens / Q000276:immunology; D014355:Chagas Disease / Q000276:immunology / Q000517:prevention & control*; D002908:Chronic Disease / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D051379:Mice; D016052:Protozoan Vaccines / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000276:immunology* / Q000472:pathogenicity; D022223:Vaccines, Subunit / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D016827:CD8 Antigens; D016052:Protozoan Vaccines; D022223:Vaccines, Subunit